International Urology and Nephrology

, Volume 28, Issue 1, pp 49–53 | Cite as

Usefulness of Cernilton in the treatment of benign prostatic hyperplasia

  • S. Dutkiewicz


A total of 89 patients with benign prostatic hyperplasia (BPH) were treated pharmacologically for 4 months: 51 received Cernilton and 38 Tadenan (controls). Significant subjective improvement was found in 78% of the patients in the Cernilton group compared to only 55% of the Tadenan-treated patients. The obstructive and irritative symptoms responded best to the therapy. In the Cernilton-treated patients a significant improvement in the uroflow rate, decrease in residual urine and in prostate volume were found. This study shows that Cernilton is an effective therapy for patients with BPH.


Benign Prostatic Hyperplasia Finasteride Prostate Volume International Urology Residual Urine Volume 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Barry, M. J.: The epidemiology and natural history of benign prostatic hyperplasia.Curr. Opin. Urol., 4, 3 (1994).CrossRefGoogle Scholar
  2. 2.
    Becker, H., Ebeling, L.: Konservative Therapie der benignen Prostata-Hyperplasie (BPH) mit Cernilton.N. Urologe [B],28, 301 (1988).Google Scholar
  3. 3.
    Dutkiewicz, S.: Benign prostatic hypertrophy. Current strategy and pharmacologic potential.Materia Medica Polona (in press).Google Scholar
  4. 4.
    Dutkiewicz, S.: Guidelines for the diagnosis and qualification for treatment of benign prostatic hyperplasia.Ter. Leki, 20/42, 29 (1992).Google Scholar
  5. 5.
    Haertig, A.: Current opinion on the therapy of BPH (in Polish). Fournier-Debat Symposium Proceedings, 15.10.1993, pp. 11–16.Google Scholar
  6. 6.
    Hald, T.: Review of current treatment of benign prostatic hyperplasia.Eur. Urol., 25 (Suppl. 1), 15 (1994).PubMedGoogle Scholar
  7. 7.
    Isaacs, J. T.: Etiology of benign prostatic hyperplasia.Eur. Urol., 25 (Suppl. 1), 6 (1994).PubMedGoogle Scholar
  8. 8.
    Lepor, H.: The treatment of benign prostatic hyperplasia with alpha-1 blockers.Curr. Opin. Urol., 4, 16 (1994).CrossRefGoogle Scholar
  9. 9.
    Loshen, G., Ebeling, L.: Hemmung der Arachidonsäure-Kaskade durch einen Extrakt aus Roggenpollen.Arzneimittelforschung, 41, 162 (1991).Google Scholar
  10. 10.
    Vahlensieck, W., Rutishauser, G. (eds): Benign Prostate Diseases. G. Thieme-Verlag, Stuttgart-New York 1992.Google Scholar

Copyright information

© Akadémiai Kiadó 1996

Authors and Affiliations

  • S. Dutkiewicz
    • 1
  1. 1.Department of UrologyCentral Clinical Hospital, Health Administration of the Capital, Ministry of Internal AffairsWarsawPoland

Personalised recommendations